0
0
Scientists have discovered that monitoring the genetic evolution of antibiotic-resistant bacteria—commonly known as “superbugs”—inside patients in real time can help doctors tailor treatments more effectively, potentially saving lives. A groundbreaking study published in Nature Communications in May highlights how this approach could transform the fight against dangerous infections.
The research, led by Dr. Stefano Giulieri of the Doherty Institute in Melbourne, Australia, focused on Staphylococcus aureus, a bacterium carried by about 30% of people. While often harmless, this microbe can cause serious infections if it overgrows and becomes resistant to multiple antibiotics, earning it the “superbug” label. The study analyzed samples from 11 patients whose infections were not responding to standard treatments, examining 60 different strains of the bacterium.
Using advanced genetic sequencing, the team identified whether each patient’s infection was “persistent” (bacteria remained after five or more days of treatment) or “recurrent” (bacteria returned after initial treatment success). They also detected signs of adaptive evolution—changes in bacterial genes that help microbes survive despite antibiotic exposure. About one-third of the strains showed these resistance-linked genetic changes, suggesting a need to switch to different antibiotics.
To assess the practical impact of these findings, researchers surveyed 25 infectious disease specialists worldwide, presenting them with patient cases both with and without the evolutionary analysis. When provided with the evolution report, 34% of the doctors altered their treatment recommendations, opting for different antibiotics or adjusting treatment duration.
“This tool can significantly impact our decision-making process,” said Dr. Quyen Nguyen, an assistant professor of medicine at the University of Pittsburgh, who was not involved in the study. “We welcome new technology that can quickly give more precise data so that we can increase confidence in our decisions,” Nguyen added.
Despite these promising results, the study acknowledged limitations, including its small sample size and the current cost and turnaround time of genomic sequencing. The authors emphasized that further research is needed to refine the framework and test it on larger patient groups.
Disclaimer:
This article is for informational purposes only and is not meant to offer medical advice. Always consult a healthcare professional for diagnosis and treatment of infections or other medical conditions.
